Highest-materiality recent filing
Bluejay Diagnostics closes $8.5M private placement with warrants for up to $23.7M total
Closed private placement of 3,655,917 common shares (or pre-funded warrants) plus Series G and H warrants at $2.325/unit, raising $8.5M gross.
Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial
SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital
Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.
Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations
Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.
Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027
Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.
Bluejay Diagnostics raises $4.5M in private placement of stock and warrants
Gross proceeds of $4.5M; net proceeds ~$4.0M after 8% placement agent fee and expenses.
Bluejay expands SanyoSeiko partnership for Symphony platform commercialization
SanyoSeiko will serve as contract manufacturing organization for analyzers, cartridges, and components.
Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027
SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.
Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding
SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.
CTO Jason Cook's employment ends May 30, 2025 under separation agreement.
Bluejay Diagnostics raises ~$3.7M via warrant inducement; existing holders exercise at reduced price
Entered inducement agreements to exercise 1,085,106 Class C warrants at reduced exercise price of $3.42/share (down from $16.30).
Bluejay Diagnostics implements 1-for-50 reverse stock split effective Nov 18, 2024
Reduces outstanding shares from ~27.6M to ~552,854, no change to par value $0.0001.
Nasdaq extended compliance deadline to Feb 24, 2025; stock must close at $1.00+ for 10 days.
Bluejay Diagnostics closes $8.75M public offering to repay debt and fund FDA work
Gross proceeds $8.75M from sale of 5,368,098 units at $1.63/unit.
Bluejay Diagnostics raises $2M in senior secured notes with equity kicker
Entered NPA for $1M note (repayable $1,176,470) and SPA for $1M notes plus 580,308 shares, both due Sept 2024.
Authorized shares of common stock increased from 7,500,000 to 50,000,000 via amendment filed May 14, 2024.
Bluejay Diagnostics terminates interim CFO; CEO assumes principal financial officer role
Frances Scally ceased as Interim CFO effective March 29, 2024, following termination of DLA agreement.
Bluejay Diagnostics receives Nasdaq deficiency notice for bid price below $1.00
Closing bid price below $1.00 for 30 consecutive business days; non-compliance with Nasdaq Listing Rule 5550(a)(2).
Bluejay Diagnostics closes $3.5M public offering of common stock and warrants
2,692,308 units sold at $1.30/unit: one share (or pre-funded warrant) plus one warrant to buy one share.
Bluejay Diagnostics Q3 net loss $2.29M; Toray license cut to 7.5% royalty
Net loss $2.29M ($2.08/share) for Q3 2023; nine-month loss $7.65M ($7.30/share).
Bluejay Diagnostics amends Toray license; royalty cut to 7.5% of net sales, supply deal for FDA path
Royalty rate reduced from 15% to 7.5% of net sales (or less) for 10-year term; 50% reduction after patent expiry.
Bluejay Diagnostics CFO Kenneth Fisher departs; Frances Scally named interim CFO
Kenneth R. Fisher ceased as CFO on September 26, 2023; may receive severance per employment agreement.
Bluejay Diagnostics H1 2023 net loss $5.4M; cash down to $5.1M; FDA meeting on IL-6 test
Net loss $5.4M ($5.24/sh) vs $4.0M ($2.00/sh) in H1 2022; no revenue reported.
Bluejay Diagnostics regains Nasdaq minimum bid price compliance after reverse stock split
Received Nasdaq notification on Aug 8, 2023 that minimum bid price deficiency is closed.
Reverse split ratio 1-for-20; authorized shares reduced from 100M to 7.5M; outstanding shares from ~20.5M to ~1.02M.
Bluejay Diagnostics updates Symphony IL-6 regulatory strategy, expands trial to sepsis patients
Trial widened from severe COVID-19 only to all hospitalized sepsis patients to speed enrollment while maintaining H1 2024 submission timeline.
Nasdaq grants Bluejay Diagnostics extension to Oct 23, 2023 to regain $1 bid price
Company received original deficiency notice on Oct 25, 2022 for bid price below $1.
Bluejay Diagnostics reports 2022 net loss $9.3M; FDA submission delayed to H1 2024
Net loss $9.3M ($0.46 per share) vs $3.5M ($0.41 per share) in 2021.
Under the terms of the Separation Agreement, Dr. Cook will cease employment with the Company on May 30, 2025.
Frances Scally, who had served as the Company’s Interim Chief Financial Officer pursuant to such agreements with DLA, ceased serving as an officer of the Company.
the Board of Directors of the Company (the “Board”) has designated Neil Dey, the Company’s President and Chief Executive Officer, as the Company’s the principal financial and accounting officer, in addition to serving as principal executive officer.
On October 14, 2023, a Separation Agreement entered into between Bluejay Diagnostics, Inc. and Kenneth R. Fisher became effective and irrevocable in connection with Mr. Fisher’s prior separation from employment on September 26, 2023.
On September 26, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Kenneth R. Fisher agreed that Mr. Fisher would depart the Company as an employee and cease serving as its Chief Financial Officer (“CFO”).
Under the these agreements, Scott Levy will complement Ms. Scally as a special advisor to the Company’s CEO.
On September 26, 2023, the Board of Directors (the “Board”) of the Company appointed Frances Scally, age 56, as interim CFO of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective immediately.
on March 23, 2022, Bluejay Diagnostics, Inc. (the “Company”) accepted the resignation of Mr. Gordon Kinder from his position as Chief Financial Officer effective immediately.
On March 23, 2022, the Company accepted the resignation of Mr. Gordon Kinder from his position as Chief Financial Officer effective immediately.
On March 23, 2022, Bluejay Diagnostics, Inc. (the “Company”) entered into an employment agreement with Mr. Kenneth Fisher pursuant to which Mr. Fisher agreed to serve as Chief Financial Officer of the Company commencing on such date.
Gary Gemignani was appointed to the board of directors of the Company.
Max materiality 0.75 · Median 0.60 · Most common event other_material